

# Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Sankha Bhattacharya<sup>1</sup>

<sup>1</sup> Narsee Monjee Institute of Management Studies

Potential competing interests: No potential competing interests to declare.

Excellent work by the authors! It's truly commendable to see researchers giving their best into the potential of Semaglutide, a GLP-1 agonist, as a preventive anti-cancer agent. This research note not only sheds light on the shared pathophysiological features between cancer and diabetes but also explores the intricate mechanisms through which GLP-1 may play a crucial role in preventing diabetes. The discussion on the promising relationship between GLP-1 receptor agonists and cancer treatment is particularly intriguing, especially when considering their impact on crucial factors like cell proliferation, apoptosis, and angiogenesis regulation. Furthermore, the emphasis on establishing optimal dosages for GLP-1 agonists highlights the meticulous approach required for their potential in addressing both diabetes and cancer prevention. Kudos to the researchers for contributing valuable insights to the field of anticancer research!